Eric Van Cutsem, MD, PhD

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Introduction Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs), is an in...

Eric Van Cutsem , MD, PhD;

07/01/2019

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

BRAF mutations occur in 8% to 12% of patients with mCRC and are associated with clinically poor prognosis. E+C was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/25/2023

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Background Tucatinib (TUC), a highly selective HER2-directed tyrosine kinase inhibitor (TKI) approved in multiple regions for HER2+ metastatic breast cancer, is being de...

Eric Van Cutsem , MD, PhD;

06/28/2021

Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

Background Approximately 10% of patients with metastatic colorectal cancer (mCRC) have BRAF mutations, predominantly V600E. Encorafenib has been approved in combination with cetuximab in ...

Eric Van Cutsem , MD, PhD;

07/02/2021

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study

Introduction Combination therapy with the anti-HER2 antibody trastuzumab with fluoropyrimidine and platinum is the current standard for patients with HER2+ metastatic gastric or gas...

Eric Van Cutsem , MD, PhD;

07/01/2019

The SUNLIGHT trial, an international, open-label, randomised, phase 3 study comparing trifluridine/tipiracil (FTD/TPI) plus bevacizumab (bev) to FTD/TPI monotherapy in patients with refra...

Eric Van Cutsem , MD, PhD;

06/25/2023

Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients

Background The Cancer Genome Atlas (TCGA) project and Asian Cancer Research Group (ACRG) recently categorized gastric cancer (GC) into molecular subtypes. Unfortunately,...

Eric Van Cutsem , MD, PhD;

06/28/2021

Emerging Concepts in HER2-Driven Gastrointestinal Cancers

Kohei Shitara , MD;

Josep Tabernero , MD, PhD;

Salvatore Siena , MD;

Eric Van Cutsem , MD, PhD;

08/16/2019

Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Background Standard-of-care (SOC) first-line therapy for HER2-positive metastatic G/GEJ cancer is trastuzumab plus chemotherapy. Adding pembrolizumab to SOC showed promising efficacy and ...

Eric Van Cutsem , MD, PhD;

07/03/2021

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

    KEYNOTE062 (NCT02494583) was a randomized, active controlled study of first-line (1L) pembrolizumab (P) or pembrolizumab plus chemotherapy (P+C) vs chemotherapy (C) in pts...

Charles S. Fuchs ;

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

07/01/2019